Document is current
Any future updates will be listed below
-
Authors
D’Alterio, C.
Rea, G.
Napolitano, M.
Coppola, E.
Spina, A.
Russo, D.
Azzaro, R.
Mignogna, C.
Scognamiglio, G.
Califano, D.
Arenare, L.
Schettino, C.
Pisano, C.
Cecere, S. C.
Di Napoli, M.
Passarelli, A.
Perrone, F.
Pignata, S.
Scala, S.
-
Funding
Funding for this research was provided by:
Pfizer and Merck (https://doi.org/10.13039/100009945)
Ministero della Salute (m2/6-c)
Fondazione AIRC per la ricerca sul cancro ETS (24746)
- License Information
-
More Information
Article History
Received: 16 January 2025
Accepted: 14 March 2025
First Online: 17 April 2025
Declarations
:
: The authors declare no competing interests.
: The research protocol was approved by Human Ethical Committee registration number 9/17–16/19 referred to ClinicalTrials.gov (NCT03503786) and EudraCT (2016–004403–31). The protocol for blood samples from healthy donors was approved by Institutional Review Boards CE 36/22 oss n.1177.
: Informed consent was obtained from all subjects involved in the study.
